Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity

Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by the US Food and Drug Administration for systemic lupus erythematosus. Experiences from the field in conducting trials of all the agents tested during this period have provided valuable practical insights. There has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Chan-Bum, Liang, Matthew H., Bae, Sang-Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718037/
https://www.ncbi.nlm.nih.gov/pubmed/26732314
http://dx.doi.org/10.1186/s13075-015-0906-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718037/
https://www.ncbi.nlm.nih.gov/pubmed/26732314
http://dx.doi.org/10.1186/s13075-015-0906-9

Ejemplares similares